Drug manufacturer AstraZeneca and two health centers aligned with Ryan White Clinics for 340B Access (RWC-340B) briefed a 340B administrative dispute resolution (ADR) panel last week on whether a recent federal court ruling has implications for the health centers’ 340B contract pharmacy-related complaints against the company.
Astra in January asked the ADR panel to stay proceedings against it pending the outcome of its case challenging the federal government’s May 2021 determination that Astra’s conditions on 340B pricing when covered entities use contract pharmacies is illegal. Astra also said the panel should stay the proceedings given that the government has said it will publish new 340B ADR regulations.
A 340B ADR panel wants to know if a judge's recent ruling in AstraZeneca's 340B contract pharmacy lawsuit has any affect on RWC-340B's dispute resolution petition against Astra and Sanofi.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
